These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32097841)

  • 1. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
    Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
    Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
    Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
    Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis.
    He L; Zhang J; Ling Z; Zeng X; Yao H; Tang M; Huang H; Xie X; Qin T; Feng X; Chen Z; Deng F; Yue X
    Bioorg Chem; 2024 Aug; 149():107499. PubMed ID: 38815476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
    He L; Pei H; Lan T; Tang M; Zhang C; Chen L
    Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
    Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
    He L; Shao M; Wang T; Lan T; Zhang C; Chen L
    Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Selective Covalent Janus Kinase 3 Inhibitors.
    Tan L; Akahane K; McNally R; Reyskens KM; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K; Johannessen L; Akbay EA; Wong KK; Frank DA; Marto JA; Look TA; Arthur JS; Eck MJ; Gray NS
    J Med Chem; 2015 Aug; 58(16):6589-606. PubMed ID: 26258521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.
    Yao H; Zhang J; Zheng Q; Zeng X; Huang H; Ling Z; Tang M; Chen Z; Wang W; He L
    Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300753. PubMed ID: 38442328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
    Norman P
    Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
    Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
    J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
    Ren J; Shi W; Zhao D; Wang Q; Chang X; He X; Wang X; Gao Y; Lu P; Zhang X; Xu H; Zhang Y
    Bioorg Med Chem; 2020 Jan; 28(2):115236. PubMed ID: 31843459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
    Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
    Sun B; Liu X; Zheng X; Wang C; Meng Q; Sun H; Shu X; Liu K; Sun X; Li Y; Ma X
    ChemMedChem; 2020 Jan; 15(2):182-187. PubMed ID: 31755225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
    Forster M; Gehringer M; Laufer SA
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor.
    Shi L; Zhong Z; Li X; Zhou Y; Pan Z
    J Med Chem; 2019 Jan; 62(2):1054-1066. PubMed ID: 30615446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Zhu Y; Zheng X; Wang C; Sun X; Sun H; Ma T; Li Y; Liu K; Chen L; Ma X
    Bioorg Med Chem; 2020 Jan; 28(2):115254. PubMed ID: 31866272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma.
    Wu B; Yang S; Deng T; Wang C; Jin Y; Yu J; Xu Y; Chen L; Li Y; Ma X
    Bioorg Chem; 2021 Nov; 116():105330. PubMed ID: 34547646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.